On January 7, 2019 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, reported that it will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 (Press release, Theravance, JAN 7, 2020, View Source [SID1234552815]). The presentation is scheduled for 8:30 a.m. PT (11:30 a.m. ET/4:30 p.m. GMT) and may be accessed by visiting the Investor Relations section of Theravance Biopharma’s website at www.theravance.com, under the Presentations and Events tab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. Audio replays will be available for 30 days following the presentation.

On January 7, 2020 Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx) has established coverage for its solid tumor molecular profile. The GTC-Solid Tumor Profile provides a comprehensive evaluation of the abnormalities in the entire coding sequence of 434 genes in various types of solid tumors (Press release, Genomic Testing Cooperative, JAN 7, 2020, View Source [SID1234553222]). This decision of covering solid tumors along with the previous coverage decision of two GTC hematology profiles allows GTC to offer comprehensive genomic profiling with next-generation sequencing (NGS) for patients with all types of cancer including a liquid biopsy for hematologic neoplasms.
Laboratories and hospitals that are members of the cooperative group as well as non-member medical professionals will have immediate access to these Medicare-covered tumor profiling tests.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Maher Albitar, GTC Chief Executive Officer and Chief Medical Officer, stated "We are delighted that Palmetto GBA now covers our hematology and solid tumor profiles. This full coverage along with our unique business model as a cooperative company will allow us to fulfill our mission in democratizing comprehensive molecular profiling of cancer and making it available and affordable for every patient with cancer." Dr Albitar added "We believe that this coverage by Medicare will help other Co-op member laboratories and large oncology practice groups obtain coverage when they adapt and or internalize our highly validated comprehensive molecular profiling tests. This will not only improve patient care, but also reduce costs and deliver better standardized Precision Medicine."
It is estimated that approximately 1.74 million Americans will be diagnosed with cancer every year and more than 14 million people are living with a diagnosis of cancer in the US. Cancer is currently the second leading cause of death in the US.

On January 7, 2020 Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, reported that chief executive officer Martin Lehr will deliver a corporate presentation at Biotech Showcase 2020, being held January 13-15, 2020, at the Hilton San Francisco Union Square in San Francisco (Press release, Context Therapeutics, JAN 7, 2020, View Source [SID1234552782]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Mr. Lehr will provide updates on Context’s lead clinical program, onapristone extended release (onapristone ER), including the Company’s ongoing Phase 2 study (ONWARD 220) evaluating onapristone ER alone in patients with progesterone receptor positive (PR+) rare ovarian and endometrial cancers, and pending combination trials in ER+,PR+,HER2- breast cancer.

Details for this presentation are as follows:

Time/Date: 4:30 p.m. PT on Tuesday, January 14, 2020

Location: Hilton San Francisco, Union Square

Room: Franciscan D (Ballroom Level)

To schedule a meeting with the Context management team, please email [email protected].

About Onapristone ER
Onapristone ER (onapristone extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers. Preliminary preclinical and clinical data suggest that onapristone ER has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. Onapristone ER is currently the subject of an ongoing Phase 2 clinical trial in progesterone receptor positive ovarian cancer. Additional Phase 2 clinical trials in breast and endometrial cancers will initiate in 2020. Onapristone ER is an investigational drug that has not been approved for marketing by any regulatory authority.

On January 7, 2020 PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, reported it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments (Press release, PhoreMost, JAN 7, 2020, View Source [SID1234552798]). Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones. Further financial terms are not disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, towards disease relevant pathways nominated by Boehringer Ingelheim. Novel targets identified will be further validated and characterised by Boehringer Ingelheim as part of its internal Discovery Research pipeline. Boehringer Ingelheim’s Research programme is active in the fields of immunology and respiratory diseases, cardiometabolic diseases, oncology research and immuno-oncology, as well as diseases of the central nervous system.

The SITESEEKER platform is based on PhoreMost’s core proprietary protein interference, or ‘PROTEINi’, technology. Using SITESEEKER, PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. This enables the systematic unmasking of cryptic druggable sites, directly linking them to useful therapeutic functions.

Dr Chris Torrance, CEO of PhoreMost, said: "We are delighted that Boehringer Ingelheim has chosen to work with PhoreMost to enhance its drug discovery pipeline with attractive biological starting points. The collaboration is further recognition of the ability of PROTEINi and SITESEEKER to identify novel targets, and we look forward to working with the Boehringer Ingelheim team on these projects."

On January 7, 2020 Danaher Corporation (NYSE: DHR) reported that it will webcast its quarterly earnings conference call for the fourth quarter 2019 on Thursday, January 30, 2020 beginning at 8:00 a.m. ET and lasting approximately 1 hour (Press release, Danaher, JAN 7, 2020, View Source [SID1234552816]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher’s website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

You can access the conference call by dialing 866-503-8675 within the U.S. or +1 786-815-8792 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher’s earnings conference call (access code 5867674). A replay of the conference call will be available shortly after the conclusion of the call until February 13, 2020. You can access the replay dial-in information on the "Investors" section of Danaher’s website under the subheading "Events & Presentations."

Danaher’s earnings press release, the webcast slides and other related presentation materials will be posted to the "Investors" section of Danaher’s website under the subheading "Quarterly Earnings" beginning at 6:00 a.m. ET on the date of the earnings call and will remain available following the call.